InsiderTrades

Form 4 for AVTX Avalo Therapeutics, Inc.

Accepted 2026-08-12 16:10:11 ET · period of report 2026-08-10 · accession 0001918845-26-000026 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-08-12 16:10 2026-08-10 AVTX Doyle Mittie Chief Medical Off M - OptEx $8.04 +679 52.5K +1% +$5,459
DT 2026-08-12 16:10 2026-08-10 AVTX Doyle Mittie Chief Medical Off S - Sale+OE $20.00 -679 51.8K -1% -$13.6K
DT 2026-08-12 16:10 2026-08-10 AVTX Doyle Mittie Chief Medical Off M - OptEx $0.00 -679 114.4K -0.6% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-08-10 M A 679 $8.04 52,455 D — — (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2 Common Common Stock 2026-08-10 S D 679 $20.00 51,776 D — — (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
3 Derivative Stock Option (Right to Buy) 2026-08-10 M D 679 $0.00 114,413 D $8.04 · — to 2035-01-28 679 Common Stock (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. (F2) The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.